UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

June 10, 2019

ENDONOVO THERAPEUTICS, INC.
Delaware 000-55453 45-2552528
(State or other jurisdiction of incorporation) (Commission File Number)
(IRS Employer Identification No.)

6320 Canoga Avenue, 15th Floor
Woodland Hills, CA 91367 (Address of principal executive office)(Zip Code)
Registrant’s telephone number, including area code: (800) 489-4774

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events.

On June 12, 2019 the Registrant completed its new marketing plan with sales projections. A copy of that plan is an Exhibit to this report.

Item 9.01 Financial Statements and Exhibits.
(a) Financial Statements: None
(b) Exhibits: 99.1 Marketing Plan with sales projections


SIGNATURES



Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: June 12, 2019

ENDONOVO THERAPEUTICS, INC.

By: /s/ Alan Collier

Alan Collier Chief Executive Officer